J4I Stock Chart & Stats
€0.01
€0.00(0.00%)
At close: 4:00 PM EDT
€0.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.01 - €0.16
Previous CloseN/A
Volume0.00
Average Volume (3M)N/A
Market Cap
€10.57M
Enterprise Value€12.65M
Total Cash (Recent Filing)€1.72M
Total Debt (Recent Filing)€75.00K
Price to Earnings (P/E)―
Beta-2.07
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding7,899,737,000
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)2.44
Price to Sales (P/S)0.00
P/FCF Ratio-4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageMinimal debt reduces repayment pressure and lowers immediate financial risk. This gives Solvonis greater flexibility to fund operations or pursue development activities without the added constraints typically created by heavy borrowing.
Positive Equity BaseA positive and growing equity base provides a solvency cushion against continued operating losses. Although returns remain negative, this capital foundation may help the company sustain operations while it seeks to improve its business performance.
Cash Burn Tracks Reported LossesThe close alignment between cash burn and reported losses suggests there are no clear signs of a materially worse cash conversion problem beyond the underlying unprofitability. This improves transparency around funding needs, even though cash generation remains negative.
Bears Say
Persistent Operating LossesRecurring operating and net losses indicate that the business has not yet established a sustainable profit model. Without a clear path to positive earnings, continued losses can erode equity and increase reliance on future financing or strategic changes.
Revenue Near ZeroRevenue falling effectively to zero signals severe weakness in commercial activity and limits the company’s ability to absorb fixed costs. The lack of recent revenue scale also makes margin improvement and a durable operating model difficult to demonstrate.
Persistent Negative Free Cash FlowSustained negative operating cash flow and free cash flow indicate that Solvonis consumes cash rather than funding itself. Worsening cash needs increase the risk of dilution, asset sales, or other financing requirements if performance does not improve.
Solvonis Therapeutics News
J4I FAQ
What was Solvonis Therapeutics’s price range in the past 12 months?
Solvonis Therapeutics lowest stock price was €0.01 and its highest was €0.15 in the past 12 months.
What is Solvonis Therapeutics’s market cap?
Solvonis Therapeutics’s market cap is €10.57M.
When is Solvonis Therapeutics’s upcoming earnings report date?
Solvonis Therapeutics’s upcoming earnings report date is Sep 24, 2026 which is in 17 days.
How were Solvonis Therapeutics’s earnings last quarter?
Solvonis Therapeutics released its earnings results on Apr 29, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Solvonis Therapeutics overvalued?
According to Wall Street analysts Solvonis Therapeutics’s price is currently Overvalued.
Does Solvonis Therapeutics pay dividends?
Solvonis Therapeutics does not currently pay dividends.
What is Solvonis Therapeutics’s EPS estimate?
Solvonis Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solvonis Therapeutics have?
Solvonis Therapeutics has 7,899,737,000 shares outstanding.
What happened to Solvonis Therapeutics’s price movement after its last earnings report?
Solvonis Therapeutics reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Solvonis Therapeutics?
Currently, no hedge funds are holding shares in DE:J4I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solvonis Therapeutics
Solvonis Therapeutics PLC focuses on the development of therapeutic solutions. The company is engaged in the development of novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders focusing on addiction and psychiatry.
Avingtrans
―
IMI plc
―
Mpac Group PLC
―
Morgan Advanced Materials
―
Smiths Group plc
―